It's a pleasure to welcome back to the microphone, Dr. David Cade, the Group Chief Medical Officer from Telix. Welcome, David. How are you today?
It's been a long time.
Yeah. Well, I'm still here and you're still here, so things can't be too bad. Telix is a market leader in the field of molecularly targeted radiation, both for imaging and hopefully soon to be therapeutic purposes. For calendar year 2026, the company is expected to generate revenues approaching $1 billion, the vast majority of which will be powered back into the company via R&D. Telix is a leader in the provision of gallium-68 for PSMA-targeted imaging of biochemical recurrence in metastatic prostate cancer. Beyond prostate cancer diagnostics, the company has an extensive program of pipeline assets focused not only on imaging, but on therapeutics for prostate, brain, and kidney cancers. Hence, over the next three years, we expect a significant change in the revenue profile and earnings of the group.
In addition, Telix recently announced the acquisition of ITM Group, which is the world's largest supplier of lutetium-177 for therapy purposes, and that acquisition is due to settle early in the new year. Welcome, David, and thank you so much for joining us. There is so much going on at Telix, it's hard to keep up. Nevertheless, our focus today is on BiPASS and the imminent launch of Pixclara. Great of you to join us today, David.
Well, thank you, John. That's a very gracious introduction, and thank you to Bell Potter for the opportunity to contribute to your healthcare conference, which has obviously got quite a following these days. During our presentation, if we go to the next slide, please. During our presentation today, I'm going to make some forward-looking statements, and I would encourage you to read these and take them into account. But I thought it would be worthwhile to start off with a very high-level perspective on Telix, and John, you alluded to the fact that the company has a very extensive pipeline, and it is quite a complex company. I'll try to distill the key elements of Telix for you right from the get-go.
Essentially, the business that we have built over the last decade has been on an extraordinarily rapid trajectory, which really is reflective of the broader radiopharma sector. Currently, we have three FDA-approved precision medicine products serving patients in prostate and now, as of September, brain cancer. I think somewhat atypically for a biopharma company of our size, we've built our own highly specialized commercial organization that's primarily in the United States, but also in Europe and locally here in Australia. This is because radiopharmaceuticals are really not the same as regular drugs. They're very different in that they require just-in-time delivery every single time, whether it's a diagnostic agent or a therapeutic agent. They also require a very significant commitment to clinical workflow, so that the workflow in a clinical practice has to be supported.
That's really very unique compared to traditional pharma and what we're used to there. We view our commercial team as a distinct advantage and as a strategic pillar of the company. We're now commercially active in 22 countries, which means that we sell a regulatory-approved product in 22 countries, and we expect that through indication expansion of the current products, through new products, and through new geographies, that that expansion will continue. We've now got 45 manufacturing sites globally, so that's 45 sites where we handle radioactivity and where we produce products for human use. This is a huge investment in infrastructure. But this is critically important and, again, a major differentiation that Telix believes is required.
If I could ask you to take one takeaway from today's session, I think it's to understand that radiopharma, really from a commercial perspective, is about to enter a period of what I would call hypergrowth. The strategy for how one competes and how one wins in this space has really changed dramatically, I would say, in the last five years. While I think that Telix has done a good job of staying abreast of those changes, and in terms of being out in front of the market, it does require making some very significant commercial decisions. John, you alluded to this. This is the reason that we've undertaken the ITM transaction to secure lutetium supply and a complementary pipeline of assets.
This year, as you mentioned, we are going to do just under $1 billion, this is U.S. dollars in revenue, so sort of AUD 1.4 billion, maybe a bit over AUD 1.4 billion, and we expect to come in at the top end of that guidance. Indeed, we have had a very good year, and our precision medicine business will exceed 25% growth year-on-year compared to prior. We expect to be able to continue this kind of growth in the future, but this is the big picture of the business that we have built over the past decade, and in particular over the last five years since we got our first approval in 2021. If we go to the next slide, please. Let us move on to our BiPASS trial, and BiPASS stands for, and it is important, every trial needs a name. This name is very important.
BiPASS stands for Biopsy of the Prostate Avoidance Stratification Study, with the key operative word here being avoidance. You will appreciate in a minute why this might be, as a male, so desirable. Next slide, please.
Currently, when a urologist is evaluating a patient who has been referred by their family doctor or their GP, typically with an elevated PSA blood test, they are referred to the urologist really to determine whether they have prostate cancer or not. When we are trying to work that out as a urologist, we rely very heavily on a biopsy. This is typically done, this is where it gets uncomfortable for the patient, this is typically done with an ultrasound probe placed transrectally to provide guidance as the biopsy is performed, and then large-gauge biopsy needles. In fact, we call them a biopsy gun. I mean, these terms are very evocative.
The biopsy needles are typically inserted transperineally, which is a very sensitive piece of anatomic real estate behind the scrotum, in front of the bum, about a postage stamp-sized piece of tissue there. It will typically require 15, sometimes 20 needles to obtain the tissue samples that we need to try to establish a diagnosis. It really depends on where the lesions are seen on the MRI scan that we do beforehand. Even if a lesion is seen on an MRI scan, we typically would sample the rest of the prostate gland because there is the chance that clinically significant prostate cancer might be elsewhere. If you think about that, distilling it to its essence, a lot of our technique and our prior thoughts were kind of a blind shotgun approach.
Let us hit this with a bunch of needles, and hopefully one of them will land and hopefully detect something. There are risks associated with prostate biopsy, things like infection, urinary retention, bleeding. Patients can develop clots in their bladder afterwards and they cannot urinate, or hematospermia, which is blood in the ejaculate, which is a relatively benign thing, but it is very. It is actually quite shocking for the patient and for their partner if it happens. Biopsy can be 10 or 20 minutes, depending on how you do it, and during this time, there is a probe in the rectum, which is probably the worst thing for the patient. Against all of that background, it is clearly not something you want if you do not need it.
So really, the BiPASS study set out to evaluate the use of PSMA PET scans being done in addition to the MRI scan to help us try to minimize the need for biopsies and minimize the need for inflicting this procedure on our patients. If you go to the next slide, this is our study. So BiPASS, it is a pivotal phase III study that has already enrolled 350 patients at sites in the United States and Australia. Enrollment of those patients completed in June. It went faster than we thought it would. Enrolled the 350 patients in about nine months. It brought in patients who had a clinical suspicion of prostate cancer, and of course, they were planned for a template biopsy. What BiPASS is it is super simple.
It is instead of having just an MRI scan prior to the biopsy, which has been our standard since 2015, this study will evaluate patients that have had an MRI scan and a gallium PSMA PET scan prior to biopsy. The endpoints for the study, they are simple as well. We are aiming to evaluate whether the sensitivity and specificity of gallium PSMA PET plus MRI is superior to MRI alone in being able to detect clinically significant prostate cancer. So what BiPASS does is that it builds on the landmark Australian studies known as PRIMARY and PRIMARY2, and they were done here in this country. What they showed was that gallium PSMA PET could safely halve the number of biopsies needed, or halve the number of patients that required biopsy, while at the same time not missing clinically significant prostate cancer. Next slide, please.
If you look at the current indications for PSMA PET, where do we sit today? This is what has evolved since first approval was granted in late 2021, so it is five years ago that PSMA PET was first approved by the U.S. FDA. There are really three established indications. There is the first one, which is initial staging before planned radical prostatectomy, and there are between 100,000 and 150,000 of those a year in the U.S. The second is what we call secondary restaging in the setting of biochemically recurrent disease, which is currently the largest indication. If you look at the literature, somewhere around 30% of men experience prostate cancer recurrence following a radical prostatectomy, and we believe that that is unacceptable and it needs urgent attention, and we believe that biochemical recurrence should be greatly diminished.
That is one of the key reasons that we need to have better diagnosis upfront at the start of the journey. Then, of course, the third indication is patient selection for radioligand therapy like Pluvicto for those with advanced disease. So that is the current state of affairs, and you can sort of see the total addressable market is about just under 700,000 PSMA PET scans for those three indications. If we go to the next slide, please, put simply, I believe this is what the future state will look like commencing in 2027. Gallium PSMA PET is clearly going to move to the frontline setting, right at the start of the patient's journey. The reason it will go there, shift right to the start of the journey, is to do two things.
Number one, adding PSMA PET to MRI will enable us to identify patients who can safely avoid biopsy without missing clinically significant disease, or as I would describe it to a patient, this will be none and done, meaning no biopsy and then you're done. The second thing is adding PSMA PET to MRI will enable us to shift to image-guided targeted biopsy. So rather than a blind template biopsy where we're using a bunch of needles, the PSMA PET scan will be able to enable us to do very targeted biopsy. So what I would describe to a patient as one and done. So one needle, maybe a small number of needles, and then the diagnosis is established. Okay, so that's biopsy. Let's move to the next slide, please, and brain cancer. Next slide.
I guess we're heading north from the pelvis up to the brain. Now, it may surprise some that, completely different change of topic, it may surprise some that fluoroethyltyrosine amino acid imaging PET, or what we, very complex medical terminology, so we call it FET PET, it's been around for many years in Australia and Europe for the imaging of brain cancer. It's really not been available or approved in the United States. I'm delighted with the team here at Telix that in September, the FDA did approve our Pixclara, which is fluoroethyltyrosine FET PET in the United States, which is really a major step forward for the assessment of patients who've got suspected recurrent disease after initial treatment of glioma.
This is a really important development for American patients, as FET PET plays a hugely significant role in the evaluation and the management of patients with malignant primary brain cancers, which is what we call glioma. FET PET as an imaging modality, it's already included in the clinical practice guidelines in the United States and in Europe, and there's also the potential, I referred earlier to indication expansion, there's also the potential for use in brain metastatic disease, which is about 10 times the size of the primary brain cancer market, and we're pursuing that indication with a great deal of vigor. We've got a phase III trial that's about to start seeking a new indication for brain metastases. So really, we look at the patient with brain cancer, and at Telix here, we don't stop. We're never satisfied.
We're always aiming to improve the way we manage and treat these patients. Next slide, please. This is really important that we've got Pixclara approved, because as we know, that if you're treating patients with glioma, one of the principal problems in assessing whether or not there's been transformation of disease from a low-grade glioma to a more aggressive grade, or where you have a high-grade glioma, particularly after treatment with chemoradiation, the MRI scan and the anatomical changes can be very nonspecific, and they can last for a very long time. These changes, after you've used chemoradiotherapy on a patient, they can even appear, say, 12 months after completion of chemoradiation treatment, when there may not even be any disease still present.
This is some data that shows in the U.S., in particular, with the FDA approval of Pixclara, there is going to be a huge increase in the use of FET PET, as there are really substantial numbers of clinicians who agree with the clinical practice guidelines that have already been established. They have the capability to perform the test, they have got access to a PET camera, and I think it is very likely we will see Pixclara following the trajectory that PSMA imaging has taken in the U.S. over the last five years since it was approved for the management of prostate cancer. Much smaller market in glioblastoma, but I think we will see a very significant uptake and a similar trajectory to what we saw in PSMA PET imaging five years ago. Next slide, please. This is our pipeline. John, I will not go into too much detail here.
You are very familiar with it, but there are a couple of salient points. We believe that to be a proper theranostics company, you will see that for each therapeutic agent, and we have got three therapeutic agents in late-stage phase III development across prostate, kidney, and brain, but adjacent to each of those therapeutic agents and the earlier therapeutic candidates, over on the right, we have got a corresponding diagnostic agent. We believe that to be a successful theranostics innovator, you need both. You can see, as I have already talked about, the precision medicine or diagnostic agents are capable of generating really significant revenues, $1 billion U.S. this year for Telix, which enables us to fund all of the R&D for the therapeutics pipeline. Couple of other salient points there, I think. Clearly, we are agnostic to the isotope. We use alpha and beta isotopes.
We use the full suite of isotopes, and that is again one of the rationales for acquiring ITM. We are agnostic to the delivery vector we use. We use small molecules, we use antibodies, we use antibody fragments, and we are open to different delivery vectors as well. Next slide, please. Look, I will finish up really briefly here. I think the key point here, and this is not to scale. I am not a finance guy. I am the Chief Medical Officer, and you do not want to be listening to me talking about the finances. This is not a revenue bridge. It is not to scale.
What it sets out to demonstrate, I think very articulately, is that there are multiple growth drivers available to us that we aim to bring to fruition in 2027, but build on the base of the 2026 revenue base, which in itself was a 25% increase on the prior year. As I alluded to at the start, there is growth within Illuccix and Gozellix, that franchise. There is growth in new products. There is Pixclara that has just been approved. We will have Zircaix approved in 2027. I am very confident about that. We will have new indications. I have just talked about BiPASS. That is an extreme example of a new indication, causing a multi-X factor increase in the TAM available to contest. There are new geographies. China and Japan are very significant. Japan is the second-largest sort of sovereign healthcare market in the world.
Telix Manufacturing Solutions, or TMS revenues, are going to be a significant contributor, and ITM has a very near-term therapeutic asset that, upon the merger of the two businesses, will bring additional revenues. With that, John, I think I'll pause there, and very happy to proceed to discussion or take any questions.
Yeah. Thank you, David. That's been a great run-through. I might just get you to go back to the slide that had the trial design for BiPASS, because I did have a question there, if we could do that. Just while we're doing that, David, with the BiPASS study, do you think the objective here is to try to avoid the removal of the prostate in men who are negative to disease? Or show up as negative to disease?
Yeah, I think, John, the first intent is to build on the Australian PRIMARY2 study resultsâ
Yeah.
âwhich was all of the usual leading academic suspects. And I say that with the greatest admiration. The folks at Peter Mac, folks at St. Vincent's here, and so forth. PRIMARY2, 660 odd patient trial showed that we can safely avoid biopsy, not even have to put a transrectal ultrasound probe in the patient and do any needles, let alone 20 needles. We can avoid that altogether in about half of patientsâ
Yeah.
âwhile at the same time not missing patients that have got prostate cancer.
That second point is really the key one. The specificity on this test has to be exceptionally high because you do not want to send men away telling them that they are clear when, in fact, there is disease there.
No, that is right. So we can safely do that. All BiPASS, and I confess, it is not even my or our particularly original thinking. BiPASS builds on the work of these academic giants in Australia, who are truly the leaders in the world.
Yeah.
Our study is simply a really well-run industry study that is collecting data to an industry standard that is submissible to the FDA. We have negotiated the design with the FDAâ
Yes.
âwhereas the PRIMARY2 study, landmark study, published in the best journal, but it was an investigator study. The data from that is not typically submissible to the FDA. Really, we have just validated PRIMARY2.
I even hate to say that. We are just building on PRIMARY2 and trying to replicate the results with high-quality industry-specified data that the FDA is going to accept.
Okay. You completed enrollment. What is that timing now?
Yes. Enrollment was done in June. By design, the study has six months follow-up, so the study data will be due around first quarter of next year.
We have sought fast-track designationâ
Yeah.
âwhich we have been granted, and with that sort of coupon, if you will, you've got that ticket in hand when you go and apply for your new drug applicationâ
Yeah.
âwhich will be a Q2 event next year.
Yeah.
You seek priority review.
Yeah. It is a new drug application. This is not an extension of your current label, so that is going to be highly advantageous for commercialization purposes as well.
Yeah. There is a lot of advantages. I mean, it costs more money to apply for a brand new de novo new drug application rather than an amendment to your existing. But it is similar to, say, with the GLP-1s, there is different NDAs for weight loss versusâ
Diabetes management, yeah.
âyeah, diabetes management. They got separate NDAs. So we are taking the same approach, and it vastly improves the funding that we can attract as a consequence.
Just one more question on Pixclara, just quickly, because we are out of time. The launch is approaching now, so where are you now with reimbursement and important matters of that nature?
Yeah. Look, you are talking Pixclara?
Yes. Pixclara.
Yeah. So, it is being used at the moment.
Yeah.
It has been launched, it is being used commercially.
Yeah.
It is used under a reimbursement code known as a NOC code, which is simply not otherwise classified.
Yes.
It requires a little bit more administrative work for the practice to ensure that the patient is covered, but then the temporary pass-through code will be available from Q1 of next year, and that is when we see the full sort of the full scale-up in terms of commercial lift.
Yeah. I noticed also you are going after the brain mets piece as well. That is a whole another discussion that we do not have time for today, but I may indeed look you up in the next couple of days, David, and have a chat about that. Thank you very much for joining us today, David. We are out of time. Really appreciate your energy this morning. So thank you very much, and we will see you soon.
Appreciate the opportunity. Thanks, John. Nice to see you.
Good on you. Thank you.
Thank you.
We are going to take a very short break, and we will be back with Radiopharma. Thank you.